Great.
Dr. Skinner, you really eloquently laid out that it's easy to focus on the low mortality, bulk and organisms where you can mass produce, and how there's maybe not as much investment into rarer or more deadly.... Then you mentioned some international participation around pull incentives.
I was wondering if you could lay that out a little more. How do we ensure that we're focusing on the most problematic micro-organisms?